Market Overview - The Shanghai Composite Index rose by 0.09% to 4089.45, while the Shenzhen Component Index fell by 0.2% to 14003.09, and the ChiNext Index decreased by 0.52% to 3312.47. The Sci-Tech Innovation Index increased by 1.53% to 1773.51 [4][5][12]. - The total trading volume in the Shanghai and Shenzhen markets reached 1.77 trillion CNY, a decrease of 701 billion CNY compared to the previous trading day, with over 3700 stocks rising, including 80 stocks hitting the daily limit [5][6]. Sector Performance - Active sectors included commercial aerospace, brain-computer interfaces, nuclear fusion, e-commerce, AI applications, and computing power themes. Conversely, the financial sector weakened, with brokerage and insurance stocks leading the declines [4][5]. - In the futures market, most contracts saw declines, with coking coal rising over 5%, while lithium carbonate and coking coal increased by over 2% [5][6]. Notable Stocks - Quantum technology stocks experienced significant movements, with ShenZhou Information hitting the daily limit and other companies like Keda Guokai and Geer Software also seeing rapid gains. This was influenced by the launch of a quantum computing center in Hefei [6][9]. - Semiconductor stocks remained strong, with Haiguang Information rising by nearly 10% and other companies in the domestic computing power supply chain also performing well [9][10]. IPO Activity - The stock of Zhizhu, which debuted on the market, opened 3.27% higher, with an IPO price of 116.20 HKD, raising approximately 4.348 billion HKD and a market capitalization expected to exceed 51.1 billion HKD [16][17]. Currency and Economic Indicators - The central bank conducted a reverse repurchase operation of 99 billion CNY with a rate of 1.40%, and the RMB to USD central parity rate was reported at 7.0197, depreciating by 10 basis points [18].

截至本周，已有25地发布2025年版医保及商保目录执行文件、22地明确召开药事会时间。该行建议持续 关注医保新纳入品种/适应症后续销售放量情况，以及商保的实际执行及支付情况。新年伊始，港股医 药板块表现亮眼，下周JPM行业大会召开在即，有望进一步催化板块行情。 该行认为，2026年板块稳中向好态势延续，后续选股逻辑或将重回基本面和估值，关注存在基本面预期 差、当前仍被低估、安全边际较大的头部个股。 智通财经APP获悉，交银国际发布研报称，2025年10月至今，内资通过港股通持有医药股的比例在小幅 下降后逐渐企稳，外资持仓整体平稳，内外资加大创新药布局的大方向不变。 ...

Group 1 - The core viewpoint of the news is that Guanhao Biological has shown significant stock price performance and financial metrics, indicating potential growth and investment interest [1][2]. - As of January 8, Guanhao Biological's stock price increased by 22.82% year-to-date, with a market capitalization of 4.51 billion yuan [1]. - The company reported a revenue of 293 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 5.52%, while the net profit attributable to shareholders decreased by 4.02% to 26.72 million yuan [2]. Group 2 - Guanhao Biological's main business segments include medical devices (73.28% of revenue), pharmaceuticals (15.21%), and leasing and other services (11.51%) [1]. - The company has a total of 27,800 shareholders as of December 31, with an average of 9,545 circulating shares per shareholder, indicating a slight increase in shareholding concentration [2]. - The company has distributed a total of 86.66 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Group 1 - The Hong Kong pharmaceutical sector is experiencing adjustments in Q4 2025 due to overseas liquidity expectations and market style rotation, leading to a weakening of concerns regarding the bubble in innovative drugs [1] - After the New Year holiday, there has been a resurgence of interest in AI healthcare and brain-computer interface sectors, with funds refocusing on Hong Kong pharmaceuticals, resulting in the Hang Seng Pharmaceutical ETF (159892) achieving a year-to-date increase of over 13% [1] - From a policy perspective, the new medical insurance directory and commercial insurance directory officially took effect on January 1, which is expected to boost the volume of selected drugs; the launch of the Chinese drug price registration system supports the domestic commercialization and international expansion of innovative drugs [1]

Group 1 - The A-share market continues to show strength in innovative drug concept stocks, with notable gains from companies such as Bibot-U nearing the daily limit and reaching a new high, and Yuandong Bio rising over 9% [1] - The National Medical Products Administration (NMPA) is set to support the "China debut" of innovative drugs, with plans to implement a data protection system for drug trials and establish exclusive market periods for pediatric and rare disease medications by 2026 [1] - The NMPA has announced further optimization of the review and approval process for urgently needed foreign drugs already on the market to meet the pressing clinical needs of patients [1] Group 2 - Notable stock performances include Bibot-U with a 19.95% increase, Yuandong Bio up 9.33%, and Hongbo Pharmaceutical rising 8.16%, among others [2] - The total market capitalization for Bibot-U is 22.3 billion, while Yuandong Bio stands at 11.5 billion, and Hongbo Pharmaceutical at 4.867 billion [2] - Year-to-date performance shows Bibot-U leading with a 70.89% increase, followed by Hongbo Pharmaceutical at 16.74% and Lai Mei Pharmaceutical at 7.59% [2]

Core Viewpoint - The Hong Kong stock market continues to adjust, but innovative pharmaceuticals are leading the gains, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising for the fourth consecutive day, surpassing the 60-day moving average [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened high and increased by 2%, with a notable performance from its constituent stocks, including Immune-Oncotherapy (up over 6%) and Hutchison China MediTech (up over 4%) [1]. - The ETF's net asset value has shown a significant increase, reflecting strong investor interest in the innovative drug sector [2]. Group 2: Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for innovative drugs, encouraging the application of urgently needed foreign-origin innovative and generic drugs in China [1][3]. Group 3: Company Developments - Recent announcements from innovative pharmaceutical companies include the acceptance of clinical trial applications for SAL0145 injection by Sinopharm and the approval of the innovative drug Rilapladib by Hengrui Medicine [3]. - Securities firms have been increasingly optimistic about the innovative drug sector, with reports from Pacific Securities, Guotai Junan, and Industrial Securities recommending continued focus on the innovative drug and medical device industry chain [3]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) tracks the Hang Seng Stock Connect Innovative Drug Select Index, which has three unique advantages: it is purely focused on innovative drug companies, has a high concentration of leading firms, and employs measures to control risks associated with less liquid stocks [4][5]. - The top ten constituent stocks of the ETF account for over 73% of its weight, indicating a strong representation of leading companies in the innovative drug sector [6].

Core Viewpoint - The innovative drug ETF Tianhong (517380) has seen significant trading activity and growth, indicating a strong interest in the innovative drug sector, which is experiencing a historic surge in IPOs and commercialization efforts [1][4]. Group 1: ETF Performance - As of January 8, 2026, the innovative drug ETF Tianhong (517380) recorded a transaction volume of 18.58 million yuan, with the tracked index HSSSHID rising by 0.92% [1]. - The latest scale of the innovative drug ETF Tianhong reached 1.578 billion yuan, with a total of 1.962 billion shares, both marking all-time highs since its inception [2]. - The net inflow of funds into the innovative drug ETF Tianhong was 89.42 million yuan, the highest since April 2025 [3]. Group 2: Market Trends - The innovative drug sector is experiencing a "volume and price increase" opportunity, with the top ten constituent stocks of the ETF heavily weighted towards leading companies like WuXi AppTec and HengRui Medicine, benefiting from a surge in business development (BD) transactions and breakthroughs in AI drug development [3]. - In 2025, the innovative drug sector achieved a historic explosion, with over 30 biotech companies successfully listed in A-shares and Hong Kong, and more than 50 companies awaiting approval, reflecting unprecedented capital activity [4]. - The sector has transitioned from mere speculation to substantial commercialization, becoming a benchmark sector with both growth potential and certainty in the current bull market [4]. Group 3: Institutional Insights - Southwest Securities noted that in early 2025, Hong Kong companies began achieving BD, leading to a rise in the innovative drug sector; a government report in March emphasized support for innovative drugs and medical devices, further boosting A-share performance [5]. - The sector experienced a significant price increase following a major BD deal worth 1.25 billion USD in May, but faced a high-level adjustment by the end of the third quarter [5]. - The firm predicts that in 2026, the innovative drug sector will shift from a broad rally to a selective stock market [5].

Core Viewpoint - The Hong Kong stock market for innovative drugs has experienced a rally since the beginning of 2026, driven by positive clinical data from Arrowhead, which has boosted sentiment in the sector [1]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (159570) has shown strong performance, with a nearly 2% increase and a trading volume exceeding 9 billion, indicating high trading activity [6]. - As of January 7, 2026, the ETF's latest scale has surpassed 24.7 billion, leading its peers in the same category [6]. - The majority of the weighted stocks in the ETF index have shown positive performance, with notable increases from companies like Sanofi and Innovent Biologics [2]. Group 2: Company News - Strong Brain Technology, a brain-computer interface "unicorn," has completed a financing round of 2 billion, second only to Musk's Neuralink [1]. - Insilico Medicine, an AI-driven pharmaceutical company, has announced a long-term collaboration with Sihuan Pharmaceutical for anti-tumor drug development, with a total cooperation amount of 888 million [1]. Group 3: Industry Trends - The innovative drug industry is expected to continue its upward trend, with catalysts on the horizon. The market anticipates a busy period for business development (BD) transactions and data disclosures in early 2026 [4]. - The upcoming J.P. Morgan Healthcare Conference is expected to attract over 8,000 global participants, showcasing advancements in biotechnology, pharmaceuticals, and medical devices [5]. - Three major trends are emerging in the industry: the continued rise of gene and cell therapies, deep integration of AI in pharmaceuticals, and the rise of emerging market players [7]. Group 4: Investment Insights - The average total package for top multinational corporations (MNCs) purchasing innovative drugs or technology platforms from China in 2025 is 2.756 billion, indicating a willingness to pay higher prices for Chinese innovations [8]. - The focus of MNCs is shifting from merely acquiring products to obtaining platforms and time, emphasizing the importance of technology platforms that can produce new molecules [10]. - Investment logic suggests that MNCs are willing to pay premiums for clinically validated assets, particularly those that can fill pipeline gaps and provide immediate revenue [11].

每经AI快讯，1月8日，创新药概念持续走强，海南海药、奥锐特、必贝特-U涨停，苑东生物、泰恩 康、汇宇制药-W、奥赛康、上海谊众等跟涨。 （文章来源：每日经济新闻） ...

Group 1 - The innovative drug sector is showing active performance, with notable stocks reaching new highs [1] - Bibete has hit an intraday high, indicating strong market interest and potential growth [1] - Yuandong Bio has increased by over 10%, reflecting positive investor sentiment and market dynamics [1] Group 2 - Other companies such as Hainan Haiyao, Aorite, Tainkang, Huiyu Pharmaceutical, and Aosaikang are also experiencing upward movement, suggesting a broader trend in the innovative drug industry [1]